Form 4: CalciMedica Chief Business Officer Boosts Stake with Share Purchase

CalciMedica's Chief Business Officer, Eric W. Roberts, a Director and 10% owner, acquired 2,000 shares of common stock at $2.88 per share.

Summary

• Eric W. Roberts, who serves as a Director, 10% Owner, and Chief Business Officer of CalciMedica, Inc. (CALC), purchased 2,000 shares of the company's common stock.
• The transaction occurred on July 18, 2025, with shares acquired at a price of $2.88 per share.
• Following this transaction, Mr. Roberts' indirect beneficial ownership through FMTC Custodian Roth IRA FBO Eric W. Roberts stands at 46,323 shares.
• His total beneficial ownership includes additional holdings: 164,706 shares directly, 49,894 shares indirectly via Oppenheimer & Co Inc. Custodian FBO Eric W Roberts Roth IRA, 10,661 shares indirectly via IRA Financial Trust Company CFBO Eric W. Roberts, 356,989 shares indirectly via Valence Investments SPV IV, LLC, 66,228 shares indirectly via Valence Investments SPV V, LLC, and 316,109 shares indirectly via Valence Investments SPV VI, LLC.

Sentiment

Score: 7

Explanation: The sentiment is positive due to an insider purchase by a key executive and significant shareholder, indicating confidence in the company's prospects. The score is not higher as it's a relatively small purchase in the context of total holdings, and a single transaction doesn't provide a comprehensive view of the company's health.

Positives

• The purchase of 2,000 shares by a high-ranking insider (Director, 10% Owner, and Chief Business Officer) indicates confidence in CalciMedica's future prospects and valuation at the current share price of $2.88.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider buying, particularly by key executives and significant shareholders, is often interpreted by the market as a positive signal, suggesting that management believes the company's stock is undervalued or that positive developments are anticipated. This transaction occurs within the broader context of the biotechnology and pharmaceutical industry, where company-specific news and insider sentiment can significantly influence investor perception.

Comparison to Industry Standards

• Insider purchases, such as this one by Eric W. Roberts, are a common occurrence across industries. While the specific amount of 2,000 shares is modest, the fact that a Director, 10% Owner, and CBO is buying indicates a level of confidence that aligns with positive insider activity observed in other biotech companies where executives invest their personal capital.
• For example, similar insider purchases have been noted in companies like BioNTech (BNTX) or Moderna (MRNA) during periods of perceived undervaluation or significant pipeline progress, signaling management's belief in future growth, though the scale and context of those companies differ significantly from CalciMedica.

Stakeholder Impact

• Shareholders may view this insider purchase as a positive signal, potentially increasing confidence in the company's stock.
• Employees may perceive this as a sign of stability and positive outlook from leadership.

Key Dates

Recommendation

Keywords

CalciMedica, CALC, Insider Purchase, SEC Form 4, Stock Acquisition, Eric W. Roberts, Chief Business Officer, Director, 10% Owner, Biotechnology, Pharmaceuticals